150 related articles for article (PubMed ID: 35951740)
21. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
22. [The ocular hypotensive effect and safety of 0.2% brimonidine].
Yu M; Li Y; Ge J
Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
[TBL] [Abstract][Full Text] [Related]
23. Effect of brimonidine tartrate on ocular hemodynamic measurements.
Lachkar Y; Migdal C; Dhanjil S
Arch Ophthalmol; 1998 Dec; 116(12):1591-4. PubMed ID: 9869786
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
Javitt J; Goldberg I
J Glaucoma; 2000 Oct; 9(5):398-408. PubMed ID: 11039742
[TBL] [Abstract][Full Text] [Related]
25. A review of neuropsychiatric adverse events from topical ophthalmic brimonidine.
Cimolai N
Hum Exp Toxicol; 2020 Oct; 39(10):1279-1290. PubMed ID: 32347114
[TBL] [Abstract][Full Text] [Related]
26. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
Adkins JC; Balfour JA
Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
[TBL] [Abstract][Full Text] [Related]
27. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
Williams GC; Orengo-Nania S; Gross RL
J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
[TBL] [Abstract][Full Text] [Related]
28. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure.
Watts P; Hawksworth N
Eye (Lond); 2002 Mar; 16(2):132-5. PubMed ID: 11988811
[TBL] [Abstract][Full Text] [Related]
29. Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers.
Jonescu-Cuypers CP; Harris A; Ishii Y; Kagemann L; Gazozi HJ; Rotenstreich Y; Chung HS; Martin B
J Ocul Pharmacol Ther; 2001 Jun; 17(3):199-205. PubMed ID: 11436940
[TBL] [Abstract][Full Text] [Related]
30. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M;
Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic brimonidine before LASIK.
Uretmen O; Ates H; Andaç K
J Refract Surg; 2003; 19(5):612. PubMed ID: 14518756
[No Abstract] [Full Text] [Related]
32. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Serle JB
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
[TBL] [Abstract][Full Text] [Related]
33. Brimonidine tartrate for the treatment of glaucoma.
Oh DJ; Chen JL; Vajaranant TS; Dikopf MS
Expert Opin Pharmacother; 2019 Jan; 20(1):115-122. PubMed ID: 30407890
[TBL] [Abstract][Full Text] [Related]
34. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
Frampton JE
Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
[TBL] [Abstract][Full Text] [Related]
35. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
Kurysheva NI
Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure.
Cantor LB; Hoop J; Katz LJ; Flartey K;
Clin Ther; 2001 Jul; 23(7):1032-9. PubMed ID: 11519768
[TBL] [Abstract][Full Text] [Related]
37. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
[TBL] [Abstract][Full Text] [Related]
38. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.
Lusthaus JA; Goldberg I
Expert Opin Drug Saf; 2017 Sep; 16(9):1071-1078. PubMed ID: 28656780
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of brimonidine in children with glaucoma.
Enyedi LB; Freedman SF
J AAPOS; 2001 Oct; 5(5):281-4. PubMed ID: 11641636
[TBL] [Abstract][Full Text] [Related]
40. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
Javitt JC; Schiffman RM
J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
